Article ID Journal Published Year Pages File Type
2575995 The American Journal of Geriatric Pharmacotherapy 2008 9 Pages PDF
Abstract
Conclusions: Compared with the IPR cohort, the FSC 500/50 cohort was 45% less likely to have a COPD-related exacerbation event and had similar medical costs. FSC 500/50 was a more effective initial maintenance therapy than IPR for this Medicare population, and, despite the $260 increase in COPD-related pharmacy costs, there was no significant difference in COPD-related medical costs.
Related Topics
Health Sciences Medicine and Dentistry Geriatrics and Gerontology
Authors
, , , , , ,